Age No Bar to Immunotherapy for Metastatic Melanoma – Journal of Clinical Pathways
|
Age No Bar to Immunotherapy for Metastatic Melanoma
Journal of Clinical Pathways NEW YORK (Reuters Health) – After immunotherapy for metastatic melanoma, patients over age 65 appear to show equivalent, and perhaps better, clinical outcome than their younger counterparts, according to a small retrospective study from France. For … |
